Get started

Abeona Therapeutics

Alternate name: Abeona Therapeutics Inc.
Description: company in Dallas, United States
Country: US
ROR: 03zvgda56
Wikidata ID: entity/Q30290505
Crossref ID: 100012233
DOI: 10.13039/100012233
OpenAlex ID: F4320313399
A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa
2021 · Jean Yuh Tang, M. Peter Marinkovich, et al. · Orphanet Journal of Rare Diseases · 123
PDF
Newborn screening for Krabbe disease in New York State: the first eight years’ experience
2016 · Joseph J. Orsini, Denise M. Kay, et al. · Genetics in Medicine · 108
PDF
Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa
2020 · Da Meng, Sara D. Ragi, et al. · Molecular Therapy · 75
PDF
Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3)
2016 · Megan E. Bosch, Amy Aldrich, et al. · Journal of Neuroscience · 69
PDF
Deep Phenotyping of Parkinson’s Disease
2020 · E. Ray Dorsey, Larsson Omberg, et al. · Journal of Parkinson s Disease · 62
PDF
Update in the Mucopolysaccharidoses
2021 · Kim L. McBride, Kevin M. Flanigan · Seminars in Pediatric Neurology · 51
Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: Results of a consensus procedure
2017 · Johanna H. van der Lee, Jonathan Morton, et al. · Molecular Genetics and Metabolism · 47
PDF
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial
2019 · Yi-Chen Zhang, Zhi-Hong Chen, et al. · EBioMedicine · 46
PDF
Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa
2022 · Jodi Y. So, Jaron Nazaroff, et al. · Orphanet Journal of Rare Diseases · 44
PDF
The future of newborn screening for lysosomal disorders
2021 · Melissa P. Wasserstein, Joseph J. Orsini, et al. · Neuroscience Letters · 43
PDF
Therapy development for the mucopolysaccharidoses: Updated consensus recommendations for neuropsychological endpoints
2020 · Johanna H. van der Lee, Jonathan Morton, et al. · Molecular Genetics and Metabolism · 36
PDF
Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
2020 · Alexander G. Mathioudakis, Adnan Custovic, et al. · The Journal of Allergy and Clinical Immunology In Practice · 35
PDF
From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
2019 · Shaundra Eichstadt, Jean Y Tang, et al. · Clinical Cosmetic and Investigational Dermatology · 34
PDF
Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis)
2018 · Erika F. Augustine, Christopher A. Beck, et al. · JIMD Reports · 33
CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
2022 · Wen-Hsuan Wu, Yi-Ting Tsai, et al. · Molecular Therapy · 32
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial
2025 · Jean Y Tang, M Peter Marinkovich, et al. · The Lancet · 31
CRISPR/Cas therapeutic strategies for autosomal dominant disorders
2022 · Salvatore Marco Caruso, Peter M.J. Quinn, et al. · Journal of Clinical Investigation · 25
PDF
The phenotypic spectrum of X‐linked, infantile onset ALG13 ‐related developmental and epileptic encephalopathy
2021 · Alexandre N. Datta, Nadia Bahi‐Buisson, et al. · Epilepsia · 23
PDF
Evaluation of biomarkers for Sanfilippo syndrome
2019 · Jennifer T. Saville, Kevin M. Flanigan, et al. · Molecular Genetics and Metabolism · 21
An observational, prospective, multicenter, natural history study of patients with mucopolysaccharidosis type IIIA
2021 · Frits A. Wijburg, Karen Aiach, et al. · Molecular Genetics and Metabolism · 20
PDF
Phenotypic Variability of Retinal Disease Among a Cohort of Patients With Variants in the CLN Genes
2023 · Masha Kolesnikova, Jose Ronaldo Lima de Carvalho, et al. · Investigative Ophthalmology & Visual Science · 19
PDF
When is the best time to screen and evaluate for treatable genetic disorders?: A lifespan perspective
2023 · Melissa A. Parisi, Michele Caggana, et al. · American Journal of Medical Genetics Part C Seminars in Medical Genetics · 19
PDF
Eleven-Year Outcomes of Deep Brain Stimulation in Early-Stage Parkinson Disease
2022 · Mallory L. Hacker, Jacqueline C. Meystedt, et al. · Neuromodulation Technology at the Neural Interface · 19
Translatability barriers between preclinical and clinical trials of AAV gene therapy in inherited retinal diseases
2023 · Alizeh Shamshad, Chaerim Kang, et al. · Vision Research · 17
Future perspectives: What lies ahead for Neuronal Ceroid Lipofuscinosis research?
2020 · Jonathan D. Cooper, Sara E. Mole · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 14
PDF
Works count: 47
Citation count: 1,122
H-index: 20
I10-index: 27
2-year mean citedness: 3.417
Awards count: 0
Year
Topic
Type